

Roche Investor Relations ASCO Planner 2018

Friday, June 1

Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia

Session Type: Oral Abstract Session

Date: Fri, June 1

Location: E450

Time: 2:45 PM - 5:45 PM

Speaker Name: Luciano J. Costa

- **3:57 PM – 4:09 PM**

Abstract 8004 Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Session Title: Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer: Caution Indicated!

Session Type: Clinical Science Symposium

Date: Fri, June 1

Location: Hall D1

Time: 4:30 PM - 6:00 PM

Speaker Name: Dong-Wan Kim, MD, PhD

- **4:42 PM - 4:54 PM**

Abstract 9009 Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

Saturday, June 2

Session Title: Genitourinary (Nonprostate) Cancer

Session Type: Poster Session

Date: Sat, June 2

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Arjun Vasant Balar, MD

- **Abstract 4523** Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. **Poster Board #349**

Session Title: Pediatric Oncology

Session Type: Poster Session

Date: Sat, June 2

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Ami Vijay Desai, MD, MSCE

- **Abstract 10536** Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. **Poster Board #209**

Sunday, June 3

Session Title: Breast Cancer—Metastatic

Session Type: Oral Abstract Session

Date: Sun, June 3

Location: Hall D2

Time: 8:00 AM - 11:00 AM

Speaker Name: Jose Baselga, MD, PhD, FASCO; Rebecca Alexandra Dent, MD

- **10:00 AM - 10:12 AM**
Abstract LBA1006 Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
- **10:24 AM - 10:36 AM**
Abstract 1008 Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

Session Title: Genitourinary (Nonprostate) Cancer

Session Type: Oral Abstract Session

Date: Sun, June 3

Location: Arie Crown Theater

Time: 8:00 AM - 11:00 AM

Speaker Name: Bernard Escudier, MD; Thomas Powles, MD

- **8:24 AM - 8:36 AM**
Abstract 4511 Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

- **10:00 AM - 10:12 AM**

Abstract 4506 A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Session Title: Gastrointestinal (Noncolorectal) Cancer

Session Type: Poster Session

Date: Sun, June 3

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: Stacey Stein, MD

- **Abstract 4074** Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). **Poster Board #263**
-

Session Title: Lung Cancer—Non-Small Cell Metastatic

Session Type: Poster Session

Date: Sun, June 3

Location: Hall A

Time: 8:00 AM - 11:30 AM

Speaker Name: D. Ross Camidge, MD, PhD; Martin Reck, MD, PhD

- **Abstract 9043** Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. **Poster Board #366**
 - **Abstract 9047** Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). **Poster Board #370**
-

Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Session Type: Oral Abstract Session

Date: Sun, June 3

Location: E450

Time: 9:45 AM - 12:45 PM

Speaker Name: Laurie Helen Sehn, MD, MPH; Peter Hillmen, M.B., Ch.B.

- **11:45 AM - 11:57 AM**

Abstract 7507 Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

- **11:57 AM - 12:09 PM**

Abstract 7508 High, durable minimal residual disease negativity (MRD-) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.

Session Title: Plenary Session Including the Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sun, June 3

Location: Hall B1

Time: 1:00 PM - 4:00 PM

Chair and/or Co-Chairs: Bruce E. Johnson, MD, FASCO; Ann H. Partridge, MD, MPH, FASCO; Daniel F. Hayes, MD, FACP, FASCO, BA; Douglas R. Lowy, MD; Joseph A. Sparano, MD; Lisa A. Carey, MD; Gianni Bisogno, MD; Douglas S. Hawkins, MD; Arnaud Mejean, MD, PhD; Daniel J. George, MD; Gilberto Lopes, MD, MBA; Leena Gandhi, MD, PhD

Monday, June 4

Session Title: Lung Cancer—Non-Small Cell Metastatic

Session Type: Oral Abstract Session

Date: Mon, June 4

Location: Hall B1

Time: 3:00 PM - 6:00 PM

Speaker Name: Robert M. Jotte, MD, PhD; Mark A. Socinski, MD

- **3:00 PM - 3:12 PM**

Abstract LBA9000 IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

- **3:45 PM - 3:57 PM**

Abstract 9002 Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Session Title: Targeted Therapy in Leukemia

Session Type: Clinical Science Symposium

Date: Mon, June 4

Location: E450

Time: 4:30 PM - 6:00 PM

Speaker Name: Courtney Denton Dinardo, MD

- **5:06 PM - 5:24 PM**

Abstract 7010 Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).

Tuesday, June 5

Session Title: Tumor Biology

Session Type: Oral Abstract Session

Date: Tue, June 5

Location: S406

Time: 8:00 AM - 11:00 AM

Speaker Name: Fatema A. Legrand, PhD; Vamsidhar Velcheti, MD; Gracy Crane

- **8:00 AM - 8:12 AM**
Abstract 12000 Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- **8:12 AM - 8:24 AM**
Abstract 12001 Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-FIRST results.
- **10:00 AM - 10:12 AM**
Abstract 12006 Application of a real world endpoint to identify and characterize genetic profiles of patients (pts) with poor prognosis in advanced non-small-cell lung cancer (aNSCLC).